Monotherapy comparative trials: equivalence and differences in clinical trials.

Area of Science:

• Clinical Trials
• Biostatistics
• Pharmacoeconomics

Background:

• Clinical trial designs typically focus on detecting differences between treatments.
• Equivalence studies are essential for assessing treatment similarity, which can be clinically significant.
• Ethical considerations, particularly in areas with existing effective treatments, limit the use of placebo-controlled trials.

Purpose of the Study:

• To highlight the importance and application of equivalence studies in clinical research.
• To explain the statistical definition and requirements for establishing treatment equivalence.
• To discuss the implications of equivalence studies for drug licensing and trial methodology.

Main Methods:

• Equivalence is defined by constraining the 95% confidence intervals of treatment comparisons within pre-defined limits.
• These studies require a larger number of subjects compared to superiority trials.
• Intention-to-treat analysis may not be the most conservative approach in equivalence studies.

Main Results:

• Equivalence studies provide a rigorous method for demonstrating that new treatments are similar to existing ones.
• This approach is particularly valuable in therapeutic areas like cancer chemotherapy and antibiotics where established treatments exist.
• The statistical framework for equivalence testing relies on confidence intervals and pre-specified margins.

Conclusions:

• Equivalence studies are vital for establishing treatment similarity and offer an ethical alternative to placebo-controlled trials.
• Rigorous definition of equivalence, based on the minimal clinically important difference, can facilitate drug licensing.
• The design and analysis of equivalence studies, including sample size and statistical methods, differ significantly from superiority trials.